Skip to main content

Market Overview

Recap: Vertex Pharmaceuticals Q3 Earnings


Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) decreased 1.4% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 114.63% over the past year to $2.64, which beat the estimate of $2.32.

Revenue of $1,538,000,000 higher by 61.92% year over year, which beat the estimate of $1,470,000,000.


Vertex Pharmaceuticals hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $6,000,000,000 and $6,200,000,000.

How To Listen To The Conference Call

Date: Oct 29, 2020

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $306.08

52-week low: $192.32

Price action over last quarter: down 23.89%

Company Description

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: Earnings